New Concepts for Primary and Secondary Hyperparathyroidism

  • Joachim Beige
  • Peter Lamesch


Primary hyperparathyroidism and secondary disease from chronic kidney disease are highlighted in this chapter. Up-to-date descriptions of new pathological mechanisms focus on fibroblastic growth factor 23 and its emergent importance in overall pathology. Historical, clinical, and examination findings are highlighted and compliment data on laboratory techniques, diagnostic imaging, and skeletal histology clinical workup of the patients. Treatment options at the dialysis and pharmacological levels are blended with some of the nutritional elements in phosphorus control. The integration of all elements is summarized at the end of the section to emphasize its influence on bone metabolism.


Primary hyperparathyroidism Insulinoma Gastrinoma Pheochromocytoma Hypercalcemia RET HRPT2 Renal function 1,25 (OH)2 vitamin D Glomerular filtration Homeostasis J-shaped curve Chronic kidney disease FGF 23 Vitamin D receptor RANK ligand Osteoclastogenesis Renal osteodystrophy Calciphylaxis Fetuin GLA protein Epitopes Serum calculation Ostase (bone alkaline phosphatase) TRAP-5b Osteitits fibrosa Parathyroidectomy Calcimimetics Ca × P product Randomized controlled trial Vascular calcification Venous sampling Parathyroid scanning Oxyphilic cells Neoplasia Osteoprotegerin Sodium thiosulfate Sestamibi Technetium 99m Osteoclasts Osteoblasts Trabecular 



The authors want to thank Dr. Gabriele Lehmann (Jena), for critical review of the bone section and gratification of histological pictures as well as Andreas Plötner, MD (Leipzig), for gratification of Fig. 5.1.

My wife (J.B.), Karin Kaori Beige, bolstered this work by fine grasp and patience.


  1. 1.
    Marcocci C, Cetani F, Rubin MR, Silverberg SJ, Pinchera A, Bilezikian JP. Parathyroid carcinoma. J Bone Miner Res. 2008;23(12):1869–80.PubMedGoogle Scholar
  2. 2.
    Kouvaraki MA, Shapiro SE, Perrier ND, et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005;15(6):531–44.PubMedGoogle Scholar
  3. 3.
    Heath III H, Hodgson SF, Kennedy MA. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med. 1980;302(4):189–93.PubMedGoogle Scholar
  4. 4.
    Mak RH, Wong JH. The vitamin D/parathyroid hormone axis in the pathogenesis of hypertension and insulin resistance in uremia. Miner Electrolyte Metab. 1992;18(2–5):156–9.PubMedGoogle Scholar
  5. 5.
    Brown EM. PTH secretion in vivo and in vitro. Regulation by calcium and other secretagogues. Miner Electrolyte Metab. 1982;8(3–4):130–50.PubMedGoogle Scholar
  6. 6.
    Brown EM, Wilson RE, Eastman RC, Pallotta J, Marynick SP. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab. 1982;54(1):172–9.PubMedGoogle Scholar
  7. 7.
    Rodriguez M, Canalejo A, Garfia B, Aguilera E, Almaden Y. Pathogenesis of refractory secondary hyperparathyroidism. Kidney Int Suppl. 2002;80: 155–60.PubMedGoogle Scholar
  8. 8.
    Felsenfeld AJ, Rodriguez M, guilera-Tejero E. Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2007;2(6):1283–305.PubMedGoogle Scholar
  9. 9.
    Holgado R, Haire H, Ross D, et al. Effect of a low calcium dialysate on parathyroid hormone secretion in diabetic patients on maintenance hemodialysis. J Bone Miner Res. 2000;15(5):927–35.PubMedGoogle Scholar
  10. 10.
    Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7): 2205–15.PubMedGoogle Scholar
  11. 11.
    Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM. FGF23 is ­processed by proprotein convertases but not by PHEX. Bone. 2004;35(2):455–62.PubMedGoogle Scholar
  12. 12.
    Rodriguez M, Felsenfeld AJ. PTH, FGF-23 and early CKD. Nephrol Dial Transplant. 2008;23(11): 3391–3.PubMedGoogle Scholar
  13. 13.
    Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab. 2003;285(1): E1–9.PubMedGoogle Scholar
  14. 14.
    Yu X, White KE. FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev. 2005;16(2):221–32.PubMedGoogle Scholar
  15. 15.
    Canalejo R, Canalejo A, Martinez-Moreno JM, et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol. 2010;21(7):1125–35.PubMedGoogle Scholar
  16. 16.
    Panda DK, Miao D, Bolivar I, et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem. 2004;279(16):16754–66.PubMedGoogle Scholar
  17. 17.
    Wang AY, Ho SS, Wang M, et al. Cardiac valvular calcification as a marker of atherosclerosis and arterial calcification in end-stage renal disease. Arch Intern Med. 2005;165(3):327–32.PubMedGoogle Scholar
  18. 18.
    Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol. 1998;11(5):239–45.PubMedGoogle Scholar
  19. 19.
    Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–17.PubMedGoogle Scholar
  20. 20.
    Schwarz A, Mengel M, Gwinner W, et al. Risk factors for chronic allograft nephropathy after renal transplantation: a protocol biopsy study. Kidney Int. 2005;67(1):341–8.PubMedGoogle Scholar
  21. 21.
    Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis. 2004;43(6):1104–8.PubMedGoogle Scholar
  22. 22.
    Araya CE, Fennell RS, Neiberger RE, Dharnidharka VR. Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. Clin J Am Soc Nephrol. 2006;1(6):1161–6.PubMedGoogle Scholar
  23. 23.
    Tokashiki K, Ishida A, Kouchi M, et al. Successful management of critical limb ischemia with intravenous sodium thiosulfate in a chronic hemodialysis patient. Clin Nephrol. 2006;66(2):140–3.PubMedGoogle Scholar
  24. 24.
    Meissner M, Bauer R, Beier C, et al. Sodium thiosulphate as a promising therapeutic option to treat calciphylaxis. Dermatology. 2006;212(4):373–6.PubMedGoogle Scholar
  25. 25.
    Ackermann F, Levy A, Daugas E, et al. Sodium thiosulfate as first-line treatment for calciphylaxis. Arch Dermatol. 2007;143(10):1336–7.PubMedGoogle Scholar
  26. 26.
    Pasch A, Schaffner T, Huynh-Do U, Frey BM, Frey FJ, Farese S. Sodium thiosulfate prevents vascular calcifications in uremic rats. Kidney Int. 2008;74(11): 1444–53.PubMedGoogle Scholar
  27. 27.
    Musso CG, Enz P, Vidal F, et al. Oral sodium thiosulfate solution as a secondary preventive treatment for calciphylaxis in dialysis patients. Saudi J Kidney Dis Transpl. 2008;19(5):820–1.PubMedGoogle Scholar
  28. 28.
    Hayden MR, Goldsmith DJ. Sodium thiosulfate: new hope for the treatment of calciphylaxis. Semin Dial. 2010;23(3):258–62.PubMedGoogle Scholar
  29. 29.
    Velasco N, MacGregor MS, Innes A, MacKay IG. Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy? Nephrol Dial Transplant. 2006;21(7):1999–2004.PubMedGoogle Scholar
  30. 30.
    Hermans MM, Brandenburg V, Ketteler M, et al. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 2007;72(2):202–7.PubMedGoogle Scholar
  31. 31.
    Kuzniar J, Porazko T, Klinger M. Relationship between fetuin-A concentration, elevated levels of inflammatory markers, and arterial wall stiffness in end-stage kidney disease. J Ren Nutr. 2008;18(1): 83–6.PubMedGoogle Scholar
  32. 32.
    Schafer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003;112(3): 357–66.PubMedGoogle Scholar
  33. 33.
    Koos R, Krueger T, Westenfeld R, et al. Relation of circulating Matrix Gla-Protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost. 2009;101(4):706–13.PubMedGoogle Scholar
  34. 34.
    Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004;95(6):560–7.PubMedGoogle Scholar
  35. 35.
    Bilezikian JP, Rubin M, Silverberg SJ. Asymptomatic primary hyperparathyroidism. Arq Bras Endocrinol Metabol. 2006;50(4):647–56.PubMedGoogle Scholar
  36. 36.
    Bilezikian JP, Silverberg SJ. Clinical spectrum of primary hyperparathyroidism. Rev Endocr Metab Disord. 2000;1(4):237–45.PubMedGoogle Scholar
  37. 37.
    Gayed IW, Kim EE, Broussard WF, et al. The value of 99mTc-sestamibi SPECT/CT over conventional SPECT in the evaluation of parathyroid adenomas or hyperplasia. J Nucl Med. 2005;46(2):248–52.PubMedGoogle Scholar
  38. 38.
    Mihai R, Simon D, Hellman P. Imaging for primary hyperparathyroidism—an evidence-based analysis. Langenbecks Arch Surg. 2009;394(5):765–84.PubMedGoogle Scholar
  39. 39.
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;113:S1–130.Google Scholar
  40. 40.
    Klein KB, Orwoll ES, Lieberman DA, Meier DE, McClung MR, Parfitt AM. Metabolic bone disease in asymptomatic men after partial gastrectomy with Billroth II anastomosis. Gastroenterology. 1987;92: 608–16.PubMedGoogle Scholar
  41. 41.
    Merz WA, Schenk RK. Quantitative structural analysis of human cancellous bone. Acta Anat (Basel). 1970;75(1):54–66.Google Scholar
  42. 42.
    Malluche HH, Sherman D, Meyer W, Massry SG. A new semiautomatic method for quantitative static and dynamic bone histology. Calcif Tissue Int. 1982;34(5):439–48.PubMedGoogle Scholar
  43. 43.
    Lehmann G, Ott U, Kaemmerer D, Schuetze J, Wolf G. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3–5. Clin Nephrol. 2008;70(4): 296–305.PubMedGoogle Scholar
  44. 44.
    Irvin III GL, Carneiro D. Parathyroid hyperplasia: parathyroidectomy. Philadelphia: Elsevier Saunders (Textbook of Endocrine Surgery); 2005. p. 472–80. Ref Type: Serial (Book,Monograph).Google Scholar
  45. 45.
    Gotch F, Levin NW, Kotanko P. Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration. Blood Purif. 2010;29(2):163–76.PubMedGoogle Scholar
  46. 46.
    Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349(5):446–56.PubMedGoogle Scholar
  47. 47.
    Bilezikian JP, Khan AA, Potts Jr JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009;94(2):335–9.PubMedGoogle Scholar
  48. 48.
    Al-Hilali N, Hussain N, Ataia AI, Al-Azmi M, Al-Helal B, Johny KV. Hypertension and hyperparathyroidism are associated with left ventricular hypertrophy in patients on hemodialysis. Indian J Nephrol. 2009;19(4):153–7.PubMedGoogle Scholar
  49. 49.
    Evenepoel P, Claes K, Kuypers D, Maes B, Vanrenterghem Y. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant. 2005;20(8):1714–20.PubMedGoogle Scholar
  50. 50.
    Nasri H, Baradaran A, Naderi AS. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis. Acta Med Austriaca. 2004;31(3):67–72.PubMedGoogle Scholar
  51. 51.
    Piovesan A, Molineri N, Casasso F, et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf). 1999;50(3):321–8.Google Scholar
  52. 52.
    Rosenthal FD, Roy S. Hypertension and hyperparathyroidism. Br Med J. 1972;4(837):396–7.PubMedGoogle Scholar
  53. 53.
    Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90(6):3326–30.PubMedGoogle Scholar
  54. 54.
    Dotzenrath C. Indications for parathyroidectomy in renal hyperparathyroidism: comments on the significance of new therapeutics. Chirurg. 2010;81(10): 902–8.PubMedGoogle Scholar
  55. 55.
    Costa-Hong V, Jorgetti V, Gowdak LH, Moyses RM, Krieger EM, De Lima JJ. Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery. 2007;142(5): 699–703.PubMedGoogle Scholar
  56. 56.
    Alfrey AC, Jenkins D, Groth CG, Schorr WS, Gecelter L, Ogden DA. Resolution of hyperparathyroidism, renal osteodystrophy and metastatic calci­fication after renal homotransplantation. N Engl J Med. 1968;279(25):1349–56.PubMedGoogle Scholar
  57. 57.
    Egbuna OI, Taylor JG, Bushinsky DA, Zand MS. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant. 2007;21(4):558–66.PubMedGoogle Scholar
  58. 58.
    Lee PP, Schiffmann L, Offermann G, Beige J. Effects of parathyroidectomy on renal allograft survival. Kidney Blood Press Res. 2004;27(3):191–6.PubMedGoogle Scholar
  59. 59.
    Schwarz A, Rustien G, Merkel S, Radermacher J, Haller H. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant. 2007;22(2):584–91.PubMedGoogle Scholar
  60. 60.
    Evenepoel P, Claes K, Kuypers DR, Debruyne F, Vanrenterghem Y. Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrol Dial Transplant. 2007;22(6):1730–7.PubMedGoogle Scholar
  61. 61.
    Lorenz K, Ukkat J, Sekulla C, Gimm O, Brauckhoff M, Dralle H. Total parathyroidectomy without autotransplantation for renal hyperparathyroidism: experience with a qPTH-controlled protocol. World J Surg. 2006;30(5):743–51.PubMedGoogle Scholar
  62. 62.
    Wells Jr SA, Gunnells JC, Shelburne JD, Schneider AB, Sherwood LM. Transplantation of the parathyroid glands in man: clinical indications and results. Surgery. 1975;78(1):34–44.PubMedGoogle Scholar
  63. 63.
    Paloyan E, Lawrence AM, Paloyan D. Successful autotransplantation of the parathyroid glands during total thyroidectomy for carcinoma. Surg Gynecol Obstet. 1977;145(3):364–8.PubMedGoogle Scholar
  64. 64.
    Brennan MF, Brown EM, Marx SJ, et al. Recurrent hyperparathyroidism from an autotransplanted parathyroid adenoma. N Engl J Med. 1978;299(19):1057–9.PubMedGoogle Scholar
  65. 65.
    D’Avanzo A, Parangi S, Morita E, Duh QY, Siperstein AE, Clark OH. Hyperparathyroidism after thyroid surgery and autotransplantation of histologically normal parathyroid glands. J Am Coll Surg. 2000;190(5):546–52.PubMedGoogle Scholar
  66. 66.
    de Menezes Montenegro FL, Custodio MR, Arap SS, et al. Successful implant of long-term cryopreserved parathyroid glands after total parathyroidectomy. Head Neck. 2007;29(3):296–300.PubMedGoogle Scholar
  67. 67.
    Brennan MF, Brown EM, Spiegel AM, et al. Autotransplantation of cryopreserved parathyroid tissue in man. Ann Surg. 1979;189(2):139–42.PubMedGoogle Scholar
  68. 68.
    Al-Sobhi SCO. Parathyroid hyperplasia: parathyroidectomy. Philadelphia: Elsevier Saunders (Textbook of Endocrine Surgery); 2005. p. 481–8. Ref Type: Serial (Book, Monograph).Google Scholar
  69. 69.
    Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516–25.PubMedGoogle Scholar
  70. 70.
    Mizobuchi M, Hatamura I, Ogata H, et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol. 2004;15(10):2579–87.PubMedGoogle Scholar
  71. 71.
    Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol. 2005;288(2):F253–64.PubMedGoogle Scholar
  72. 72.
    Colloton M, Shatzen E, Miller G, et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int. 2005;67(2):467–76.PubMedGoogle Scholar
  73. 73.
    Chertow GM, Pupim LB, Block GA, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol. 2007;2(5):898–905.PubMedGoogle Scholar
  74. 74.
    Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68(4):1793–800.PubMedGoogle Scholar
  75. 75.
    Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005;20(7):1311–4.PubMedGoogle Scholar
  76. 76.
    Apostolou T, Damianou L, Kotsiev V, Drakopoulos S, Hadjiconstantinou V. Treatment of severe hypocalcaemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet. Clin Nephrol. 2006;65(5):374–7.PubMedGoogle Scholar
  77. 77.
    Borchhardt KA, Heinzl H, Mayerwoger E, Horl WH, Haas M, Sunder-Plassmann G. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation. 2008;86(7):919–24.PubMedGoogle Scholar
  78. 78.
    Lopez V, Toledo R, Sola E, et al. Treatment with cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism. Transplant Proc. 2009;41(6):2394–5.PubMedGoogle Scholar
  79. 79.
    Serra AL, Savoca R, Huber AR, et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant. 2007;22(2):577–83.PubMedGoogle Scholar
  80. 80.
    Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18.PubMedGoogle Scholar
  81. 81.
    Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167(9):879–85.PubMedGoogle Scholar
  82. 82.
    Dhingra R, Gona P, Benjamin EJ, et al. Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community. Eur J Heart Fail. 2010;12(8): 812–8.PubMedGoogle Scholar
  83. 83.
    USDA National Nutrient Database for Standard Reference, Release 17. Accessed at Nov 2nd 2010.
  84. 84.
    Kuhlmann MK. Practical approaches to management of hyperphosphatemia: can we improve the current situation? Blood Purif. 2007;25(1):120–4.PubMedGoogle Scholar
  85. 85.
    Granja CA, Juergensen P, Finkelstein FO. Phosphate balance in peritoneal dialysis patients: role of ultrafiltration. Contrib Nephrol. 2009;163:198–205.PubMedGoogle Scholar
  86. 86.
    Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int. 1998;53:1399–404.PubMedGoogle Scholar
  87. 87.
    Jenkins DA, Gouldesbrough D, Smith GD, Cowie JF, Winney RJ. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity? Nephrol Dial Transplant. 1989;4(1):51–6.PubMedGoogle Scholar
  88. 88.
    Nakamura M, Suzuki H, Ohno Y, et al. Oral calcium carbonate administration ameliorates the progression of renal failure in rats with hypertension. Am J Kidney Dis. 1995;25:910–7.PubMedGoogle Scholar
  89. 89.
    Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004;19(6):1489–96.PubMedGoogle Scholar
  90. 90.
    Zacharias JM, Fontaine B, Fine A. Calcium use increases risk of calciphylaxis: a case-control study. Perit Dial Int. 1999;19(3):248–52.PubMedGoogle Scholar
  91. 91.
    Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant. 2005;20(8):1653–61.PubMedGoogle Scholar
  92. 92.
    Ferreira A, Frazao JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008;19(2):405–12.PubMedGoogle Scholar
  93. 93.
    Izumi M, Morita S, Nishian Y, et al. Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films. Ren Fail. 2008;30(10):952–8.PubMedGoogle Scholar
  94. 94.
    McIntyre CW, Patel V, Taylor GS, Fluck RJ. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant. 2002;17(9):1643–8.PubMedGoogle Scholar
  95. 95.
    Nagano N, Miyata S, Abe M, Wakita S, Kobayashi N, Wada M. Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease. Clin Calcium. 2005;15 Suppl 1:35–9. discussion 39–40.PubMedGoogle Scholar
  96. 96.
    Takei T, Otsubo S, Uchida K, et al. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clin Pract. 2008;108(4):c278–83.PubMedGoogle Scholar
  97. 97.
    Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72(9):1130–7.PubMedGoogle Scholar
  98. 98.
    Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf. 2003;26(15):1093–115.PubMedGoogle Scholar
  99. 99.
    Feng L, Xiao H, He X, et al. Neurotoxicological consequence of long-term exposure to lanthanum. Toxicol Lett. 2006;165(2):112–20.PubMedGoogle Scholar
  100. 100.
    Finn WF. Lanthanum carbonate versus standard ­therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol. 2006;65(3):191–202.PubMedGoogle Scholar
  101. 101.
    Albaaj F, Hutchison AJ. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients. Expert Opin Pharmacother. 2005;6(2):319–28.PubMedGoogle Scholar
  102. 102.
    Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010;362(14):1312–24.PubMedGoogle Scholar
  103. 103.
    Block GA, Brillhart SL, Persky MS, Amer A, Slade AJ. Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int. 2010;77(10): 897–903.PubMedGoogle Scholar
  104. 104.
    Ahmed MH. Niacin as potential treatment for dyslipidemia and hyperphosphatemia associated with chronic renal failure: the need for clinical trials. Ren Fail. 2010;32(5):642–6.PubMedGoogle Scholar
  105. 105.
    Eknoyan G. Salivary phosphorus binding: a novel approach to control hyperphosphatemia. J Am Soc Nephrol. 2009;20(3):460–2.PubMedGoogle Scholar
  106. 106.
    Savica V, Calo LA, Monardo P, et al. Salivary ­phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol. 2009;20(3):639–44.PubMedGoogle Scholar
  107. 107.
    Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res. 2001;16(1): 113–9.PubMedGoogle Scholar
  108. 108.
    Khan AA, Bilezikian JP, Kung AW, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89(7):3319–25.PubMedGoogle Scholar
  109. 109.
    Gallacher SJ, Dixon T. Impact of Treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int. 2010;87(6):469–84.PubMedGoogle Scholar
  110. 110.
    Cejka D, Kodras K, Bader T, Haas M. Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH(1-34)): A Pilot Study. Kidney Blood Press Res. 2010;33(3):221–6.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Nephrology and KfH Renal UnitHospital St. GeorgLeipzigGermany
  2. 2.Department of Endocrinological SurgeryHospital St. GeorgLeipzigGermany

Personalised recommendations